“Emerging data for PT150 and PT157 show promising results in ex-plant models for pancreatic cancer, glioblastoma and treatment-resistant prostate cancer”
![](https://poptestllc.com/wp-content/uploads/2020/07/Palisades-Therapeutics-Drug-Pipeline-V4-01-1-1024x663.jpg)
ASCO20 Scientific Program Abstract
PT150
A new modulator of glucocorticoid and androgen receptors with antiviral activity against SARS-CoV-2
PT150
A novel glucocorticoid and androgen receptor modulator reduces viral entry and innate immune inflammatory responses in the Syrian Hamster model of SARS-CoV-2
PT Oncology Drug Platform
Glucocorticoid & Androgen Receptor Antagonist/Modulators for Oncology
National Cancer Institute Study Results on Multiple Cancers
PT150 Oncology Studies
PT157 Oncology Studies
![](https://poptestllc.com/wp-content/uploads/2020/07/1-1024x806.jpg)
![](https://poptestllc.com/wp-content/uploads/2020/07/2-1024x800.jpg)
PT162 Oncology Studies
PT167 Oncology Studies
![](https://poptestllc.com/wp-content/uploads/2020/07/3-1024x801.jpg)
![](https://poptestllc.com/wp-content/uploads/2020/07/4-1024x810.jpg)
Palisades Therapeutics new class of Antibiotics granted patent
The Palisades Therapeutics’ Potentiating Agents as broad-spectrum adjunctive therapeutics (Recently patented proprietary compounds as a platform).